Having trouble accessing articles? Reset your cache.

Boston Biomedical reports updated data from Phase Ib/II trial of amcasertib in solid tumors

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported updated data from 14 patients with advanced adenoid cystic carcinoma (ACC) in an

Read the full 262 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE